Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | YAP1 | P46937 | 2/20 | 0.34 |
| ▸ | STS | P08842 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17956491 | 0.88 | KMT2A (0.36) | USP30KMT2AL3MBTL1NPC1RAB9A | |
| SCHEMBL17956366 | 0.87 | USP30 (0.38) | USP30KMT2AL3MBTL1YAP1STS | |
| SCHEMBL17956418 | 0.82 | GPR119 (0.36) | USP30KMT2AL3MBTL1YAP1STS | |
| SCHEMBL17956404 | 0.81 | GPR119 (0.36) | USP30KMT2AL3MBTL1YAP1STS | |
| SCHEMBL17956445 | 0.81 | HDAC1 (0.39) | USP30KMT2ANPC1RAB9AYAP1 | |
| SCHEMBL17956406 | 0.81 | KMT2A (0.37) | USP30KMT2AL3MBTL1YAP1STS | |
| SCHEMBL17956439 | 0.80 | GPR119 (0.38) | USP30L3MBTL1YAP1STS | |
| SCHEMBL17956511 | 0.80 | GPR119 (0.40) | STS | |
| SCHEMBL17956448 | 0.80 | HTR5A (0.34) | USP30KMT2AALDH1A1 | |
| SCHEMBL17956374 | 0.80 | STS (0.37) | USP30RAB9ASTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000491-B2 | Process for producing diazabicyclooctane derivative and intermediate thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-10000492-B2 | Process for producing diazabicyclooctane derivative | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20170283415-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-10-05 | — | — | US | disclosed |
| US-20160264573-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3050883-A1 | PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIARY BODY THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2016-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000492-B2 | Process for producing diazabicyclooctane derivative | OGFOD1, HAAO, CLCN2 | USP30 2537/4885KMT2A 2276/4885L3MBTL1 3014/4885 |
| US-20170283415-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE | OGFOD1, HAAO, CLCN2 | USP30 2537/4885KMT2A 2276/4885L3MBTL1 3014/4885 |
| US-20160264573-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF | CLCN2, ODC1, KCNN4 | USP30 3438/4885KMT2A 1933/4885L3MBTL1 2419/4885 |
| US-10000491-B2 | Process for producing diazabicyclooctane derivative and intermediate thereof | CLCN2, ODC1, KCNN4 | USP30 3438/4885KMT2A 1933/4885L3MBTL1 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.